Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) EBIT: 2022-2024

Historic EBIT for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $47.0 million.

  • Entrada Therapeutics' EBIT fell 117.25% to -$47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.6 million, marking a year-over-year decrease of 310.37%. This contributed to the annual value of $47.0 million for FY2024, which is 1586.75% up from last year.
  • Entrada Therapeutics' EBIT amounted to $47.0 million in FY2024, which was up 1,586.75% from -$3.2 million recorded in FY2023.
  • Entrada Therapeutics' 5-year EBIT high stood at $47.0 million for FY2024, and its period low was -$97.2 million during FY2022.
  • In the last 3 years, Entrada Therapeutics' EBIT had a median value of -$3.2 million in 2023 and averaged -$17.8 million.
  • Data for Entrada Therapeutics' EBIT shows a peak YoY surged of 1,586.75% (in 2024) over the last 5 years.
  • Entrada Therapeutics' EBIT (Yearly) stood at -$97.2 million in 2022, then skyrocketed by 96.75% to -$3.2 million in 2023, then spiked by 1,586.75% to $47.0 million in 2024.